Serial ctDNA to understand PARPi resistance

IF 12.1 1区 医学 Q1 UROLOGY & NEPHROLOGY
Annette Fenner
{"title":"Serial ctDNA to understand PARPi resistance","authors":"Annette Fenner","doi":"10.1038/s41585-024-00984-7","DOIUrl":null,"url":null,"abstract":"<p>Poly(ADP-ribose) polymerase inhibition (PARPi) is an effective therapy for castration-resistant prostate cancer (CRPC) with defects in homologous recombination repair (HRR) genes. However, resistance to PARPi can arise, for example via mutations that restore <i>BRCA</i> function. Reversion mutations in HRR genes can result in PARPi resistance, but these cannot arise in patients with homozygous mutations, possibly explaining why patients with homozygous <i>BRCA2</i> mutations exhibit more durable responses to PARPi. The mechanisms of resistance in patients with homozygous mutations is unknown and how such mutations occur is not well understood.</p><p>A study in <i>Cancer Cell</i> has sought to elucidate these mechanisms, using data from the phase II TOPARP-B trial, which demonstrated antitumour activity of olaparib in patients with metastatic CRPC who had biallelic DNA-damage repair mutations. Notably, the most durable responses were seen in patients with <i>BRCA2</i> homozygous deletion. These data were also supported by the PROFound trial, which showed reduced radiological progression-free survival (rPFS) in patients with <i>BRCA2</i> heterozygous mutations compared with those with a homozygous mutation.</p>","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"18 1","pages":""},"PeriodicalIF":12.1000,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41585-024-00984-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Poly(ADP-ribose) polymerase inhibition (PARPi) is an effective therapy for castration-resistant prostate cancer (CRPC) with defects in homologous recombination repair (HRR) genes. However, resistance to PARPi can arise, for example via mutations that restore BRCA function. Reversion mutations in HRR genes can result in PARPi resistance, but these cannot arise in patients with homozygous mutations, possibly explaining why patients with homozygous BRCA2 mutations exhibit more durable responses to PARPi. The mechanisms of resistance in patients with homozygous mutations is unknown and how such mutations occur is not well understood.

A study in Cancer Cell has sought to elucidate these mechanisms, using data from the phase II TOPARP-B trial, which demonstrated antitumour activity of olaparib in patients with metastatic CRPC who had biallelic DNA-damage repair mutations. Notably, the most durable responses were seen in patients with BRCA2 homozygous deletion. These data were also supported by the PROFound trial, which showed reduced radiological progression-free survival (rPFS) in patients with BRCA2 heterozygous mutations compared with those with a homozygous mutation.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Nature Reviews Urology
Nature Reviews Urology 医学-泌尿学与肾脏学
CiteScore
12.50
自引率
2.60%
发文量
123
审稿时长
6-12 weeks
期刊介绍: Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline. The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals. Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信